Asklepios BioPharmaceutical, Inc. ' Product Pipeline Review ' 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Asklepios BioPharmaceutical, Inc. ' Product Pipeline Review ' 2012
Published on December 2012

Report Summary


Summary

Global Market Direct's pharmaceuticals report, "Asklepios BioPharmaceutical, Inc. - Product Pipeline Review - 2012" provides data on
the Asklepios BioPharmaceutical, Inc.'s research and development focus. The report includes information on current developmental
pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Asklepios
BioPharmaceutical, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Asklepios
BioPharmaceutical, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Asklepios BioPharmaceutical, Inc. - Brief Asklepios BioPharmaceutical, Inc. overview including business description, key information
and facts, and its locations and subsidiaries.
- Review of current pipeline of Asklepios BioPharmaceutical, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Asklepios BioPharmaceutical, Inc. with complete description of the
product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Asklepios BioPharmaceutical, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Asklepios BioPharmaceutical, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Asklepios BioPharmaceutical, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Asklepios BioPharmaceutical, Inc.'s R&D portfolio and develop key strategic
initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Asklepios BioPharmaceutical, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Asklepios BioPharmaceutical, Inc. and identify potential opportunities in those
areas.

Asklepios BioPharmaceutical, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Asklepios BioPharmaceutical, Inc. Snapshot 5
Asklepios BioPharmaceutical, Inc. Overview 5
Key Information 5
Key Facts 5
Asklepios BioPharmaceutical, Inc. ' Research and Development Overview 6
Key Therapeutic Areas 6
Asklepios BioPharmaceutical, Inc. ' Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products ' Monotherapy 9
Asklepios BioPharmaceutical, Inc. ' Pipeline Products Glance 10
Asklepios BioPharmaceutical, Inc. Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Asklepios BioPharmaceutical, Inc. ' Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Asklepios BioPharmaceutical, Inc. ' Drug Profiles 13
AskBio-009 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Biostrophin 14
R&D Progress 14
BNP-CHF 15
R&D Progress 15
BNP-FIX 16
R&D Progress 16
BNP-FVIII 17
R&D Progress 17
BNP-OA 18



R&D Progress 18
BNP-RP 19
R&D Progress 19
BNP-TLE 20
R&D Progress 20
Micrograft 21
R&D Progress 21
Asklepios BioPharmaceutical, Inc. ' Pipeline Analysis 22
Asklepios BioPharmaceutical, Inc. ' Pipeline Products by Therapeutic Class 22
Asklepios BioPharmaceutical, Inc. ' Pipeline Products by Route of Administration 23
Asklepios BioPharmaceutical, Inc. ' Pipeline Products By Mechanism of Action 24
Asklepios BioPharmaceutical, Inc. ' Locations And Subsidiaries 25
Head Office 25
Financial Deals Landscape 26
Asklepios BioPharmaceutical, Inc., Deals Summary 26
Asklepios BioPharmaceutical, Inc., Pharmaceuticals & Healthcare, Deal Details 27
Partnerships 27
ALS Therapy Enters Into Co-Development Agreement With Asklepios 27
Licensing Agreements 28
Asklepios BioPharma Enters Into Licensing Agreement With REGENX Biosciences For Hemophilia A 28
Asklepios BioPharma Enters Into Licensing Agreement With Pfizer 29
Asklepios BioPharma Enters Into Licensing Agreement With GlaxoSmithKline 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables

Asklepios BioPharmaceutical, Inc., Key Information 5
Asklepios BioPharmaceutical, Inc., Key Facts 5
Asklepios BioPharmaceutical, Inc. ' Pipeline by Indication, 2012 7
Asklepios BioPharmaceutical, Inc. ' Pipeline by Stage of Development, 2012 8
Asklepios BioPharmaceutical, Inc. ' Monotherapy Products in Pipeline, 2012 9
Asklepios BioPharmaceutical, Inc. ' Phase I, 2012 10
Asklepios BioPharmaceutical, Inc. ' Pre-Clinical, 2012 11



Asklepios BioPharmaceutical, Inc. ' Discovery, 2012 12
Asklepios BioPharmaceutical, Inc. ' Pipeline By Therapeutic Class, 2012 22
Asklepios BioPharmaceutical, Inc. ' Pipeline By Route of Administration, 2012 23
Asklepios BioPharmaceutical, Inc. ' Pipeline Products By Mechanism of Action, 2012 24
Asklepios BioPharmaceutical, Inc., Deals Summary 26
ALS Therapy Enters Into Co-Development Agreement With Asklepios 27
Asklepios BioPharma Enters Into Licensing Agreement With REGENX Biosciences For Hemophilia A 28
Asklepios BioPharma Enters Into Licensing Agreement With Pfizer 29
Asklepios BioPharma Enters Into Licensing Agreement With GlaxoSmithKline 30

List of Figures

Asklepios BioPharmaceutical, Inc. ' Pipeline by Indication, 2012 7
Asklepios BioPharmaceutical, Inc. ' Pipeline by Stage of Development, 2012 8
Asklepios BioPharmaceutical, Inc. ' Monotherapy Products in Pipeline, 2012 9
Asklepios BioPharmaceutical, Inc. ' Pipeline By Therapeutic Class, 2012 22
Asklepios BioPharmaceutical, Inc. ' Pipeline By Route of Administration, 2012 23
Asklepios BioPharmaceutical, Inc. - Pipeline Products By Mechanism of Action, 2012 24


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Asklepios BioPharmaceutical, Inc. ' Product Pipeline Review ' 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Asklepios BioPharmaceutical, Inc. ' Product Pipeline Review ' 2012